Revolution Medicines Inc. Warrant (RVMDW)
Stock · NASDAQ · Health Care
$8.65as of 10/16/2026
Price chart
Active signals
High Beta100.0%
BOLL Breakdown96.6%Resistance level
$11.51
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About RVMDW
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 883
Fundamentals
- 1-day range
- $8.17$9
- Market cap
- $2.25B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 4.91
- Avg. volume
- —
52-week range
$0.2311$13.44
Revolution Medicines Inc. Warrant Competitors
Chosen by industry and closest market cap.
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsYahoo · 10/9/2026
- Revolution Medicines CEO on Defeating the RAS GeneYahoo · 10/7/2026
- First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)Yahoo · 10/7/2026
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersYahoo · 10/6/2026
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic CancerYahoo · 10/5/2026
- Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS SaysYahoo · 9/28/2026
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034Yahoo · 9/28/2026
- Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?Yahoo · 9/25/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 10.15M
- Total value held
- $17.25M
- Institutional holders
- 24
Top holders this quarter
- Unknown3.84M
- Unknown1.58M
- Unknown958.8K
- Unknown583.6K
- Unknown579.5K
- Unknown517.7K
- Unknown500.0K
- Unknown450.0K
- Unknown250.0K
- Unknown200.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Revolution Medicines wins FDA breakthrough status for RASONQUE
Revolution Medicines received FDA Breakthrough Therapy designation for RASONQUE, a treatment for pancreatic cancer. This milestone highlights the company's progress in its RAS(ON) program. The news has drawn attention to the stock's valuation and risk profile following the regulatory win.
Revolution Medicines wins FDA breakthrough status for RASONQUE. Revolution Medicines received FDA Breakthrough Therapy designation for RASONQUE, a treatment for pancreatic cancer. This milestone highlights the company's progress in its RAS(ON) program. The news has drawn attention to the stock's valuation and risk profile following the regulatory win.